Tumor Mutation Burden and Tumor Microenvironment as Biomarkers of Glioma Treatment Outcome and Prognosis- A Systematic Review and Meta-Analysis Protocol-Reference-Cited by-同舟云学术

Tumor Mutation Burden and Tumor Microenvironment as Biomarkers of Glioma Treatment Outcome and Prognosis- A Systematic Review and Meta-Analysis Protocol

Published:2023-01-04 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Kyaruzi Victor¹,Md Emmanuel²,Takoutsing Berjo³,Abdelhammed Ahmed⁴,Sikakulya Franck⁵,Wekesa Emmanuel⁶,Ngamba Ramadhani⁷,Sabas Deodatus⁸,Rabiel Happines⁹,Shabhay Zarina¹⁰,Mchome Laurent¹⁰,Esene Ignatius¹¹,Mwakigonja Amos¹²

Affiliation:

1. Department of Surgery , School of Medicine , Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania.

2. Department of Oncology, Arusha Lutheran Medical Centre, Arusha, Tanzania

3. Research Department, Association of Future African Neurosurgeons, Yaounde , Cameroon

4. Faculty of Medicine, University of Al-Azhar , Egypt

5. Department of Surgery, Faculty of Clinical Medicine and Dentistry, Kampala International University, Ishaka ,Uganda

6. Department of Neurosurgery, Tenwek Mission Hospital, Bomet , Kenya

7. Department of Molecular Biology, National Institute for Medical Research, Dar es salaam, Tanzania.

8. Directorate of Library Services, Muhimbili University of Health and Allied Sciences

9. Department of Neurosurgery, Kilimanjatoro Christian Medical Centre, Kilimanjaro, Tanzania

10. Department of Neurosurgery, Muhimbili Orthopedic Institute, Dar es salaam Tanzania

11. Divisionof Neurosurgery, Faculty of Health Sciences, University of Bamenda , Bambili, Cameroon

12. Department of Pathology , School of Medicine , Muhimbili University of Health and Allied Sciences, Dar es salaam, Tanzania.

Abstract

Abstract Background Gliomas are the most common solid malignant tumors of the brain; diffuse gliomas pose a remarkable conundrum on treatment strategy. WHO Grade IV (Glioblastomas) delineate a refractory resistance to treatment even with standard combination regimen therapy of surgery, chemotherapy and radiation therapy causing increased recurrence rate with a median survival of less than one year(1). Management of gliomas is precluded by several factors including intra and inter tumoral heterogeneity, genomic landscape and microenvironment immunosuppression ability, which spell the inflicted pathways that counteract the therapeutic interventions. This is systematic review aiming to evaluate the effect of tumor mutation burden (TMB) and Tumor microenvironment (TME) as biomarkers of treatment outcome and prognosis of gliomas. Methods and Analysis This systematic Review and Meta –analysis will consider the PRISMA 2020 guideline correspondence. For source of literature evidence several electronic databases including EMBASE, PubMed, Cochrane Library, SCOPUS, Web of Science, Semantic Scholar and Google scholar will be searched. All non-RCTs peer reviewed original research articles addressing the prognostic role of tumor mutation burden, tumor mutation pathways, microenvironment will be included, and data will be extracted using the Ms Excel Sheets. Studies with homogeneity and low risk of bias according to NOS 4–9 will constitute a Meta-analysis for evaluating the effect of TMB, Mutation pathways and Microenvironment for treatment outcome and prognosis of glioma. Ethical Consideration and Dissemination Ethical approval does not apply for there is no human participant involvement in this review study .The findings of this study will be disseminated at scientific conferences and the manuscript for publication will be submitted for publication to a reputable peer reviewed journal of Neurosurgery. This review was registered at PROSPERO CRD42022377829

Publisher

Research Square Platform LLC

Reference10 articles.

1. Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas;Ahmad H;Neuro-Oncology Pract,2019

2. Tumor mutation burden, expressed neoantigens and the immune microenvironment in diffuse gliomas;Yu G;Cancers (Basel),2021

3. Kang K, Xie F, Wu Y, Wang Z, Wang L, Long J, et al. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma. Int Immunopharmacol [Internet]. 2021;96(March):107610. Available from: https://doi.org/10.1016/j.intimp.2021.107610

4. Lee M, Samstein RM, Valero C, Chan TA, Morris LGT. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Hum Vaccines Immunother [Internet]. 2020;16(1):112–5. Available from: https://doi.org/10.1080/21645515.2019.1631136

5. Tumor mutational burden as a predictor of immunotherapy response: Is more always better?;Strickler JH;Clin Cancer Res,2021